Arabic Arabic English English French French German German
dark

Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the U.S Department of Defense. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

40% of eligible population have had boosters; 28 community cases; 2 deaths; 31 people in hospital; two in ICU

Next Post

The unexpected benefits of fat in type 2 diabetes

Related Posts
Total
0
Share